PHARMACEUTICALS PROJECT SUCCESS
TEVA PHARMACEUTICALS RAM STUDY
Executed a Reliability Availability Maintainability Study for the Commercial GMP API Manufacturing Facility (Hybrid Commercial Facility) in the Conceptual Phase of the Genesis Project. The Hybrid Commercial Facility was based on the Base Scenario: 4 x 5.000 litre bioreactors (Production Line 1) + 4 x 15.000 litre bioreactors (Production Line 2).
MERCK & CO. PHARMACEUTICAL COMPANY RAM STUDY
Executed a Reliability Availability Maintainability (RAM) Analysis for the Merck Project C/CMV Launch Facility during the FEL-3 Basis of Design Phase.
MERCK & CO. PHARMACEUTICAL COMPANY OPERATIONAL READINESS
Supported Merck’s MSDC Asset Reliability Management-Centre of Excellence Architects with development of the Asset Management Capital Projects Platform Practice Guide and business process map overview; and assisted in the embedment of this platform within Global Engineering Solutions Road Map.
MERCK & CO. PHARMACEUTICAL COMPANY ASSET MANAGMENT CAPEX PLATFORM BUSINESS SYSTEM DEVELOPMENT
Developed the business process, engineering procedure, and template documentation to support these Asset Management CAPEX Platform deployment activities: Defect Discovery & Prevention, Production Availability Assurance, Total Cost of Ownership, Design for Maintainability Operability Reliability, Strategic Spare Parts Strategy, and OpEx for Reliability & Maintenance Management. Computational Fluid Dynamics (CFD) to assess water accumulation in the CVG Line and sediment settling in the emulsion Line, corrosion simulation, topography mapping, risk assessment, and design modifications.
MERCK & CO. PHARMACEUTICAL COMPANY RAM STUDY
Executed a Reliability Availability Maintainability (RAM) Analysis to evaluate the Availability impact of the pre-investment options.
MERCK & CO. PHARMACEUTICAL COMPANY COST OF OWNERSHIP ANALYSIS
Performed Total Cost of Ownership (TCO) analysis for Carlow 2 to quantitatively justify the value of the design modifications implemented on Carlow 2 (relative to Carlow 1), which impact asset redundancy, system buffering, and improvements to asset design margins, reliability, and maintainability. This analysis will be used to justify similar design modifications on other current and future projects.
MERCK & CO. PHARMACEUTICAL COMPANY RAM STUDY
Executed a Reliability Availability Maintainability (RAM) Analysis to validate the Operational Availability (or capacity) for Project Flash, BCG Production facility during the FEL-3 Basis of Design Phase.
MERCK & CO. PHARMACEUTICAL COMPANY RAM STUDY & COST OF OWNERSHIP ANALYSIS
Executed a high rigor Total Cost of Ownership (TCO) analysis to evaluate the ownership costs for various design scoping options for Project Rathgall during the Concept phase (FEL-2). The TCO analysis will be based on inputs from a Reliability Availability Maintainability (RAM) analysis utilizing historical data from the Enterprise Asset Management System (EAMS) and other relevant sources.
MERCK & CO. PHARMACEUTICAL COMPANY RAM STUDY
Executed a Reliability Availability Maintainability (RAM) Analysis to validate redundancy reduction options for the Liquid, GTS, and PWDR Production Lines for Project USH during the FEL-2 Conceptual Phase. The scope of the analysis included utilities and process systems.